| | Study | Sample size | Age (years) | Sex M/F | Intervention measures | Treatment duration (days) | Outcomes | Adverse events | | I/C | I/C | I/C | I | C |
| | [14] | 28/28 | Not reported | Not reported | A + SBP 45 mg tid | A | 42 | (b) | None | | [15] | 60/60 | I: 55.7 ± 3.2
C: 58.6 ± 4.4 | I: 27/33
C:31/29 | QSC 0.9 g tid | A | 84 | (b) + (c) | Upper abdominal discomfort | | [16] | 19/19 | Not reported | Not reported | A+
TXLC 1.04 g tid | A | 84 | (b) + (d) + (e) | Not reported | | [17] | 34/32 | Not reported | Not reported | A+
SBP 45 mg tid | A | 180′ | (c) + (d) | Not reported | | [18] | 37/33 | I: 57 ± 15
C: 58 ± 13 | I: 10/27
C: 9/24 | A+
SBP 45 mg tid | A | 180 | (a) | None | | [19] | 35/30 | I: 50.7 ± 6.3
|C: 51.3 ± 7.5 | I: 19/16
C: 17/13 | A+
SBP 45 mg tid | A | 90 | (c) + (d) + (e) | Not reported | | [20] | 34/34 | I: 45.7 ± 6.9
C: 42.2 ± 6.0 | I: 15/19
C: 16/18 | A+
TXLC 0.78 g tid | A | 180 | (b) + (d) + (e) | Not reported | | [21] | 20/18 | I: 51.00 ± 8.45
C: 51.95 ± 8.48 | I: 7/13
C: 5/13 | A+
STDP 70 mg tid | A | 84 | (b) + (c) | Not reported | | [22] | 30/32 | I: 46.5 ± 3.3
C: 46.3 ± 3.2 | I: 0/30
C: 0/32 | A+
TXLC 1.04 g tid | A | 90 | (d) + (e) | Headaches | | [23] | 41/41 | I: 53.35 ± 1.43
C: 53.13 ± 1.26 | I: 14/27
C: 16/25 | A+
YXTC 1.32 g tid | A | 28 | (b) + (d) + (e) | None | | [24] | 43/44 | I: 57.3 ± 11.9
C: 56.1 ± 13.2 | I: 23/20
C: 23/21 | A+
YXSC 0.8 g tid | A | 180 | (a)+(c)+ (d)+(e) | Not reported | | [25] | 30/30 | I: 48.93 ± 5.06
C: 47.77 ± 5.86 | I: 7/23
C: 5/25 | A+
XKSP 1.24 g tid | A | 90 | (c) + (d) | Not reported | | [26] | 38/39 | I: 69.97 ± 8.48
C: 70.46 ± 7.75 | I: 15/23
C: 18/21 | A+
XKSP 1.24 g tid | A | 180 | (c) | Not reported | | [27] | 97/97 | I: 63.0 ± 11.9
C: 65.0 ± 7.0 | I: 23/20
C: 23/21 | A+
QYDP 0.5 g tid | A | 365 | (a) + (b) | None | | [28] | 32/32 | I: 41.38 ± 9.43
C: 45.75 ± 10.61 | I: 18/14
C: 20/12 | A+
SBP 45 mg tid | A | 365 | (a) | Not reported | | [29] | 54/52 | I: 62.71 ± 5.32
C: 61.98 ± 5.39 | I: 24/30
C: 23/29 | A+
STDP 70 mg tid | A | 84 | (b) + (c) + (d) + (e) | Not reported | | [30] | 36/36 | I: 61.23 ± 6.37
C: 60.92 ± 6.14 | I: 18/18
C: 19/17 | A+
STDP 70 mg tid | A | 180 | (a) | Not reported | | [31] | 34/34 | I: 65.43 ± 4.29
C: 65.41 ± 4.27 | I: 14/20
C: 15/19 | A+
QSC 0.9 g tid | A | 60 | (d) + (e) | Headaches, dizziness, insomnia, nausea, vomiting, abdominal pain, palpitations | | [32] | 65/65 | I: 57.82 ± 4.79
C: 58.17 ± 3.36 | I: 28/37
C: 30/35 | A+
YXLC 0.8 g tid | A | 180 | (d) + (e) | Palpitations diarrhea loss of appetite nausea and vomiting | | [33] | 20/20 | I: 52.25 ± 10.14
C: 53.14 ± 9.10 | I: 11/9
C: 12/8 | A+
TXLC 1.04 g tid | A | 180 | (c) | None | | [34] | 39/39 | I: 62.71 ± 7.24
C: 64.55 ± 6.14 | I: 18/21
C: 20/19 | A+
SBP 22.5 mg tid | A | 90 | (a) + (d) + (e) | Not reported |
|
|
I, intervention group; C, control group; M, male; F, female; SBP, shexiang baoxin pill; QSC, qi shen capsule; TXLC, tong xin luo capsule; STDP, shexiang tongxin drop pill; YXSC, yindan xinnaotong soft capsule; YXTC, yu xin tong capsule; XKSP, xin ke shu pill; QYDP, qishen yiqi drop pill; A, conventional western medical treatment; (a) IMR; (b) TET; (c) hs-CRP; (d) ET-1; (e) NO.
|
